Advertisement
Screener

ASTRAZENECA PLC (AZN) Form 6-K: Report of foreign private issuer, 2023

2.4 / 5 stars · 19/40 Roast Me

Add as a preferred source on Google

ASTRAZENECA PLC Form 6-K: Report of foreign private issuer

Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.

  • 2023-12-27: Form 6-K; Period of report 2023-12-27; Description ASTRAZENECA ACQUIRES GRACELL; Document a8499x.htm.
  • 2023-12-26: Form 6-K; Period of report 2023-12-26; Description FORM 6-K; Document tm2332933d9_6k.htm.
  • 2023-12-22: Form 6-K; Period of report 2023-12-22; Description WAINUA (EPLONTERSEN) GRANTED FIRST US FDA APPROVAL; Document a7568x.htm.
  • 2023-12-14: Form 6-K; Period of report 2023-12-14; Description DIRECTOR/PDMR SHAREHOLDING; Document a7197w.htm.
FiledFormPeriod of reportDescriptionDocument
2023-12-276-K2023-12-27ASTRAZENECA ACQUIRES GRACELLa8499x.htm
2023-12-266-K2023-12-26FORM 6-Ktm2332933d9_6k.htm
2023-12-226-K2023-12-22WAINUA (EPLONTERSEN) GRANTED FIRST US FDA APPROVALa7568x.htm
2023-12-146-K2023-12-14DIRECTOR/PDMR SHAREHOLDINGa7197w.htm
2023-12-126-K2023-12-12ASTRAZENECA TO ACQUIRE ICOSAVAXa4665w.htm
2023-12-126-K2023-12-12FORM 6-Ktm2332587d1_6k.htm
2023-12-016-K2023-12-01BLOCK LISTING INTERIM REVIEWastrazenecaplc4370v.htm
2023-12-016-K2023-12-01TOTAL VOTING RIGHTSastrazenecaplc4368v.htm
2023-12-016-K2023-12-01DISCONTINUATION OF TWO CRYSTALIZE EVIDENCE TRIALSa2725v.htm
2023-11-246-K2023-11-24DIRECTOR/PDMR SHAREHOLDINGa5089u.htm
2023-11-176-K2023-11-17TRUQAP APPROVED IN US FOR HR+ BREAST CANCERa8163t.htm
2023-11-146-K2023-11-14UPDATE ON PACIFIC-2 PHASE III TRIAL FOR IMFINZIa3046t.htm
2023-11-096-K2023-11-09DIRECTOR DECLARATIONa9564s.htm
2023-11-096-K2023-11-09IMFINZI COMBINATION IMPROVES PFS IN LIVER CANCERa8746s.htm
2023-11-096-K2023-11-09AGREEMENT WITH ECCOGENE FOR CLINICAL STAGE GLP-1RAa8748s.htm
2023-11-096-K2023-11-029M AND Q3 2023 RESULTSa8671s.htm
2023-11-016-K2023-11-01TOTAL VOTING RIGHTSa0614s.htm
2023-11-016-K2023-11-01ASTRAZENECA CELL & GENE THERAPY DEAL W/ CELLECTISa0076s.htm
2023-10-036-K2023-10-03ASTRAZENECA SETTLES NEXIUM LIABILITY LITIGATIONSa4476o.htm
2023-10-026-K2023-10-02TOTAL VOTING RIGHTSa3963o.htm
2023-09-256-K2023-09-22DATO-DXD IMPROVED PFS IN BREAST CANCERa3495n.htm
2023-09-206-K2023-09-20ALEXION COMPLETES PFIZER GENE THERAPY AGREEMENTa9801m.htm
2023-09-156-K2023-09-15ENHERTU RECOMMENDED IN EU FOR HER2-MUTANT NSCLCa6521m.htm
2023-09-116-K2023-09-11FASENRA PHASE III EGPA TRIAL MET PRIMARY ENDPOINTa0602m.htm
2023-09-066-K2023-09-06UPDATE ON US REVIEW OF ULTOMIRIS FOR NMOSDa5429l.htm
2023-09-016-K2023-09-01TOTAL VOTING RIGHTSa1442l.htm
2023-08-016-K2023-08-01TOTAL VOTING RIGHTSa9376h.htm
2023-07-286-K2023-07-28ALEXION ENTERS GENE THERAPY AGREEMENT WITH PFIZERa4885h.htm
2023-07-286-K2023-06-30FORM 6Kazn-20230630x6k.htm
2023-07-176-K2023-07-17BEYFORTUS APPROVED IN US FOR INFANT RSV PREVENTIONa2876g.htm
2023-07-036-K2023-07-03TOTAL VOTING RIGHTSa7310e.htm
2023-07-036-K2023-07-03DATO-DXD SIGNIFICANTLY IMPROVED PFS IN LUNG CANCERa7145e.htm
2023-06-096-K2023-06-09NIRSEVIMAB RECOMMENDED FOR INFANT RSV PROTECTIONa1835c.htm
2023-06-096-K2023-06-09ASTRAZENECA AGREEMENT WITH QUELL THERAPEUTICSa1802c.htm
2023-06-026-K2023-06-02IMFINZI IMPROVED PCR IN GASTRIC AND GEJ CANCERSa5527b.htm
2023-06-016-K2023-06-01BLOCK LISTING INTERIM REVIEWa3634b.htm
2023-06-016-K2023-06-01TOTAL VOTING RIGHTSa3629b.htm
2023-06-016-K2023-06-01LYNPARZA APPROVED IN US FOR BRCAM PROSTATE CANCERa2598b.htm
2023-05-266-K2023-05-26IMFINZI + LYNPARZA PROLONGED PFS IN ENDOMETRIAL CANCERa7382a.htm
2023-05-226-K2023-05-22DIRECTORATE CHANGEa0345a.htm
2023-05-176-K2023-05-17TAGRISSO PLUS CHEMO IMPROVED PFS IN LUNG CANCERa6468z.htm
2023-05-096-K2023-05-09DIRECTOR/PDMR SHAREHOLDINGa7956y.htm
2023-05-096-K2023-05-09FARXIGA EXTENDED IN THE US FOR HEART FAILUREa7679y.htm
2023-05-026-K2023-05-02TOTAL VOTING RIGHTSa1403y.htm
2023-05-026-K2023-05-02ODAC VOTE ON LYNPARZA COMBO IN PROSTATE CANCERa9895x.htm
2023-05-026-K2023-05-02DIRECTOR/PDMR SHAREHOLDINGa9436x.htm
2023-04-276-K2023-04-271ST QUARTER RESULTSa6110x.htm
2023-04-276-K2023-04-27RESULT OF AGMa7661x.htm
2023-04-276-K2023-04-27BOARD COMMITTEE CHANGESa6063x.htm
2023-04-276-K2023-04-27FORM 6-Ktm2313842d1_6k.htm
2023-04-266-K2023-04-26DIRECTOR DECLARATIONa5926x.htm
2023-04-116-K2023-04-11UPDATE TO ARRANGEMENTS WITH SOBI AND SANOFIa7325v.htm
2023-04-056-K2023-04-05LYNPARZA + IMFINZI MET ENDPOINT IN OVARIAN CANCERastrazenecaplcmasterform6.htm
2023-04-036-K2023-04-03TOTAL VOTING RIGHTSa1773v.htm
2023-04-036-K2023-04-03ULTOMIRIS RECOMMENDED FOR NMOSD EU APPROVALastrazenecaplcmasterform6.htm
2023-03-306-K2023-03-30ASTRAZENECA COMPLETES KYM AGREEMENT FOR CMG901a6729u.htm
2023-03-276-K2023-03-27DIRECTOR/PDMR SHAREHOLDINGa2248u.htm
2023-03-226-K2023-03-22NOTICE OF AGMa8689t.htm
2023-03-226-K2023-03-22FORM 6-Ktm239753d1_6k.htm
2023-03-096-K2023-03-09IMFINZI IMPROVED EFS IN RESECTABLE LUNG CANCERa3671s.htm
2023-03-086-K2023-03-08DIRECTOR/PDMR SHAREHOLDINGa2152s.htm
2023-03-086-K2023-03-08DIRECTOR/PDMR SHAREHOLDINGa2148s.htm
2023-03-066-K2023-03-06ENHERTU DESTINY-PANTUMOR02 SHOWS POSITIVE RESULTSa9303r.htm
2023-03-036-K2023-03-03FORM 6-Ktm237224d8_6k.htm
2023-03-016-K2023-03-01TOTAL VOTING RIGHTSa5417r.htm
2023-03-016-K2023-03-01ASTRAZENECA PRICES A $2.25BN BOND OFFERINGa4263r.htm
2023-02-246-K2023-02-24ASTRAZENECA PRICES A EUR1.5BN BOND OFFERINGa0512r.htm
2023-02-246-K2023-02-24ASTRAZENECA ACQUIRES CINCOR FOR CARDIORENAL ASSETa0333r.htm
2023-02-246-K2023-02-24DIRECTOR/PDMR SHAREHOLDINGa9851q.htm
2023-02-236-K2023-02-23ASTRAZENECA ENTERS AGREEMENT WITH KYM FOR CMG901a7769q.htm
2023-02-226-K2023-02-22FILING OF FORM 20-F WITH SECa6118q.htm
2023-02-216-K2023-02-21ANNUAL FINANCIAL REPORTa5771q.htm
2023-02-216-K2023-02-21FORM 6-Ktm2230344d3_6k.htm
2023-02-136-K2023-02-13DIRECTOR/PDMR SHAREHOLDINGa7351p.htm
2023-02-136-K2023-02-13DIRECTOR/PDMR SHAREHOLDINGa7340p.htm
2023-02-096-K2023-02-09FINAL RESULTSa3767p.htm
2023-02-016-K2023-02-01TOTAL VOTING RIGHTSa6087o.htm
2023-01-266-K2023-01-26UPDATE ON EVUSHELD US EUAa0287o.htm
2023-01-176-K2023-01-17ACQUISITION OF NEOGENE THERAPEUTICS COMPLETEDa7540m.htm
2023-01-116-K2023-01-11AIRSUPRA (PT027) APPROVED IN US FOR ASTHMAa4253m.htm
2023-01-096-K2023-01-09ASTRAZENECA ACQUIRE CINCOR FOR CARDIORENAL ASSETa0188m.htm
2023-01-036-K2023-01-03TOTAL VOTING RIGHTSa5305l.htm
Advertisement